What's New
Thanks to Generosity of AFTD Ambassador, Californians Receive Crucial Financial Help
Terry Walter, an AFTD Ambassador in California and Nevada, has been a force for positive change and support since 2008, when she began volunteering for AFTD. Over the years she…
Protected: A Conversation with a Neurologist at Denali Therapeutics
There is no excerpt because this is a protected post.
AFTD Care Partner Learning Series Webinar: Navigating the Holidays with an FTD Diagnosis
The changes brought on by an FTD diagnosis can make navigating the holidays difficult. The routine changes of travel, large crowds, and busy days can lead to unsuccessful holiday experiences.…
Young Caregiver Talks About Finding Support Amid FTD Journey on Dementia UK Podcast
A young FTD caregiver named Lizzie discussed the grief, uncertainty, and unexpected responsibilities she faced as she cared for her father — all while navigating the natural changes of young…
Advancing Hope: AFTD Staff Attend NORD Breakthrough Summit in Washington, DC
Shana Dodge, PhD, AFTD’s Director of Research Engagement and Meghan Buzby, MBA, AFTD’s Director of Advocacy and Volunteer Engagement attended the National Organization for Rare Disorders (NORD) Breakthrough Summit, held…
GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP
South Korean biopharmaceutical company GemVax & Kael announced in late October the results from its phase 2a clinical trial evaluating a drug for PSP. While the drug failed to show…
Dear HelpLine: Navigating Travel During the Holidays
Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this would be the first time taking my wife since she was diagnosed with…
A Conversation with Alector’s Vice President of Clinical Development
Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to…
Vesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN
Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the…
November 24, 2024: In-Person Meet & Greet in Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)